The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 20)

  • Avanos Medical Inc AVNS
  • Becton Dickinson and Co BDX
  • DexCom, Inc. DXCM
  • Eli Lilly And Co LLY
  • Liquidia Technologies Inc LQDA
  • Masimo Corporation MASI
  • Merck & Co., Inc. MRK
  • Neogen Corporation NEOG
  • Pfizer Inc. PFE
  • Tandem Diabetes Care Inc TNDM

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 20)

  • Alpine Immune Sciences Inc ALPN
  • Aralez Pharmaceuticals Inc ARLZ
  • Avadel Pharmaceuticals PLC (ADR) AVDL
  • Cesca Therapeutics Inc KOOL
  • Dynavax Technologies Corporation DVAX
  • Exelixis, Inc. EXEL
  • Novan Inc NOVN )(reported positive results for its SB414 in two complementary Phase 1b clinical trials)
  • Sellas Life Sciences Group Inc SLS
  • Surface Oncology Inc SURF
  • Sinovac Biotech Ltd. SVA(announced conclusion of SEC investigation on allegations of some employees making improper payments to Chinese government officials)
  • Trinity Biotech plc (ADR) TRIB

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Stocks In Focus

FDA Approves Expanded Label For Merck's Keytruda

Merck announced the FDA has approved an expanded label for its Keytruda, with the drug in combination with pemetrexed and platinum chemotherapy now being approved as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations.

The company said the approval was based on data from the KEYNOTE-189 trial.

ProPhase Labs Q2 Loss Narrows

ProPhase Labs Inc PRPH reported a second-quarter net sales from continuing operations of $3.2 million compared to $1.9 million in the year-ago period. The company's net loss narrowed from 14 cents per share in Q217 to 2 cents per share in Q218.

On The Radar

Earnings

Medtronic PLC MDT Q1 Adj. EPS $1.17 Beats $1.11 Estimate, Sales $7.4B Beat $7.24B Estimate
Myriad Genetics, Inc. MYGN (after the close)

Date
▲▼
ticker
▲▼
name
▲▼
Actual EPS
▲▼
EPS Surprise
▲▼
Actual Rev
▲▼
Rev Surprise
▲▼
Posted In: BiotechEarningsNewsFDATop StoriesTrading Ideas
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...